News and Announcements
Positive Data on RECCE® 327 Against Neisseria gonorrhoeae in STD Animal Model
- Published May 03, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights:
- Statistically significant reduction of Neisseria gonorrhoeae bacteria in reproductive organs of female mice
- RECCE® 327 outperformed market approved drug Meropenem in most instances
Sydney Australia, 4 May 2020: Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing a New Class of Broad-Spectrum Synthetic antibiotics, today announced positive efficacy showing significant antibacterial activity against Neisseria gonorrhoeae bacteria in mice treated with its lead compound RECCE® 327.
The study was conducted by an independent Contract Research Organisation to assess the dose-dependency of RECCE® 327 and in-vivo antibacterial activity against Neisseria gonorrhoeae (N. gonorrhoeae), a species of Gram-negative bacteria, and the second most common sexually transmitted infection (STI) globally.1 The recognised vaginal infection model met its primary endpoint of a reduction in bacterial load compared to vehicle infected control evaluated on the seventh day following dosing.
To read the full update click here.
About Recce Pharmaceuticals Ltd (ASX: RCE)
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad-spectrum activity designed to address the urgent global health problem of antibiotic-resistant superbugs.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
